Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer

Crizotinib is a tyrosine kinase inhibitor (TKI) indicated in first-line treatment of rearranged c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) metastatic non-small-cell lung cancer (NSCLC). However, the common response reported after treatment is partial and few complete responses have...

Descripción completa

Detalles Bibliográficos
Autores principales: Amrane, Karim, Campedel, Luca, Le Meur, Coline, Abgral, Ronan, Kharroubi, Dris, Cadranel, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514716/
https://www.ncbi.nlm.nih.gov/pubmed/34660618
http://dx.doi.org/10.3389/fmed.2021.691253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514716/
https://www.ncbi.nlm.nih.gov/pubmed/34660618
http://dx.doi.org/10.3389/fmed.2021.691253

Ejemplares similares